A Phase I Study to Evaluate VE-202 in Single and Multi-Dose Cohorts in Healthy Volunteers
Latest Information Update: 07 Jul 2021
At a glance
- Drugs VE 202 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Janssen Research & Development
- 30 Jun 2021 Results presented in a PureTech Health Media Release.
- 09 Jun 2020 According to a Vedanta Biosciences media release, more complete study dataset and analyses from this study will be submitted to a peer-reviewed journal.
- 09 Jun 2020 Preliminary data from two phase I studies of VE202 (n=105) in healthy volunteers, presented in a Vedanta Biosciences media release.